Calzada Ltd (CALZF) 0.1900 $CALZF
Global Cachexia Pipeline Review, H1 2015 - 12 Companies & 16 Drug Profiles
M2 - Mon Jun 08, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmlmn9/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aphios Corporation - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Calzada Limited - Cytokinetics, Inc. - GlaxoSmithKline plc - MI.TO. Technology S.r.L. - Myos Corporation - Novartis AG - Palatin Technologies, Inc. - Pfizer Inc. - Rhythm Pharmaceuticals Drug Profiles - AOD-9604 - AV-380 - bimagrumab - BL-5040 - CK-2066260 - DLN-101 - dronabinol - Drugs to Inhibit Activin Receptor for Cachexia - PF-06260414 - Protein for Musculoskeletal Disorders - relamorelin - Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia - Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Small Molecules to Modulate Melanocortin-4 Receptor for Cachexia - Synthetic Peptide to Antagonize MC3 and MC4 Receptor for Cachexia For more information visit http://www.researchandmarkets.com/research/cmlmn9/cachexia
CYTK: 8.76 (-0.07), PFE: 34.26 (+0.11), AVEO: 0.90 (+0.02), PTN: 0.65 (+0.05), GSK: 43.42 (-0.16), NVS: 81.48 (-0.55)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 3.44 (-0.10), SRPT: 57.83 (-3.14)
Bone Degeneration - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/mtq3mr/bone_degeneration) has announced the addition of the "Bone Degeneration - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alethia Biotherapeutics Inc. - Calzada Limited - CTI BioPharma Corp. - GliaMed, Inc. - Histocell S.L. - TechnoPhage SA - TissueGene, Inc. For more information visit http://www.researchandmarkets.com/research/mt...generation
CTIC: 0.38 (-0.01)
Global Cachexia Pipeline Review, H1 2015 - 12 Companies & 16 Drug Profiles
M2 - Mon Jun 08, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmlmn9/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aphios Corporation - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Calzada Limited - Cytokinetics, Inc. - GlaxoSmithKline plc - MI.TO. Technology S.r.L. - Myos Corporation - Novartis AG - Palatin Technologies, Inc. - Pfizer Inc. - Rhythm Pharmaceuticals Drug Profiles - AOD-9604 - AV-380 - bimagrumab - BL-5040 - CK-2066260 - DLN-101 - dronabinol - Drugs to Inhibit Activin Receptor for Cachexia - PF-06260414 - Protein for Musculoskeletal Disorders - relamorelin - Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia - Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Small Molecules to Modulate Melanocortin-4 Receptor for Cachexia - Synthetic Peptide to Antagonize MC3 and MC4 Receptor for Cachexia For more information visit http://www.researchandmarkets.com/research/cmlmn9/cachexia
CYTK: 8.76 (-0.07), PFE: 34.26 (+0.11), AVEO: 0.90 (+0.02), PTN: 0.65 (+0.05), GSK: 43.42 (-0.16), NVS: 81.48 (-0.55)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 3.44 (-0.10), SRPT: 57.83 (-3.14)
Bone Degeneration - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/mtq3mr/bone_degeneration) has announced the addition of the "Bone Degeneration - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alethia Biotherapeutics Inc. - Calzada Limited - CTI BioPharma Corp. - GliaMed, Inc. - Histocell S.L. - TechnoPhage SA - TissueGene, Inc. For more information visit http://www.researchandmarkets.com/research/mt...generation
CTIC: 0.38 (-0.01)
